Clinical trial · Observational
Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer
Moderated Accelerated RAdiotherapy (MARA-2) in Moderate-high Risk Breast Cancer: a Phase I-II Study
NCT03471741CI-TRIAL-00032170completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3D-RT with sequential boost | Radiation | — | UNRESOLVED |
| IMRT with concomitant boost | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MARA-2: IMRT with concomitant boost
- description
- A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
- interventionNames
- Radiation: IMRT with concomitant boost
- label
- CG: 3D-RT with sequential boost
- description
- The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
- interventionNames
- Radiation: 3D-RT with sequential boost
Primary outcomes (1)
- measure
- Incidence of treatment.related late adverse events
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed invasive breast cancer (pT1-4) with at least one of these characteristics: 3 or more metastatic axillary nodes, pre or peri-menopausal status, close resection margins * breast conservative surgery Exclusion Criteria: * positive margins * distant metastases
References
Publications (1)
- DERIVEDMacchia G, Cilla S, Buwenge M, Zamagni A, Ammendolia I, Zamagni C, Frezza GP, Valentini V, Deodato F, Morganti AG. Intensity-Modulated Radiotherapy with Concomitant Boost After Breast Conserving Surgery: A Phase I-II Trial. Breast Cancer (Dove Med Press). 2020 Nov 12;12:243-249. doi: 10.2147/BCTT.S261587. eCollection 2020. PMID 33209058